Market Cap (In USD)
1.23 Billion
Revenue (In USD)
130.19 Million
Net Income (In USD)
-24.41 Million
Avg. Volume
5663.00
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 23.71-25.73
- PE
- -
- EPS
- -
- Beta Value
- 0.14146519
- ISIN
- US4158582084
- CUSIP
- -
- CIK
- 1360214
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- Mark L. Baum
- Employee Count
- -
- Website
- http://www.harrowinc.com
- Ipo Date
- 2021-05-07
- Details
- Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer in January 2006 and is headquartered in Nashville, TN.
More Stocks
-
IMCImmuron Limited
IMC
-
FLIDYFLSmidth & Co. A/S
FLIDY
-
QNRX
-
BRLXFBoralex Inc.
BRLXF
-
IBOC
-
603758Chongqing Qin'an M&E PLC.
603758
-
RLFRLF AgTech Ltd
RLF
-
GORAFGoldrea Resources Corp.
GORAF